ReadCoor is commercializing a three-dimensional multi-omic spatial sequencing platform powered by its proprietary Fluorescent in situ Sequencing (FISSEQ) technology. The platform simultaneously reads the sequences of thousands of molecules and visualizes high-resolution 3D spatial information within whole cells and tissues, and is delivered as an integrated instrument, kits, and data analysis/visualization cloudware. FISSEQ enables sequencing across genomics, transcriptomics, proteomics, and metabolomics without disrupting cell structure, producing a 3D molecular atlas intended to inform drug target evaluation, pathogen identification, and disease diagnosis. The company’s initial product suite targets research and discovery applications in oncology, infectious disease, and neuroscience and has been validated in non-small cell lung cancer, breast cancer, and a brain atlas. ReadCoor plans to accelerate commercialization and expand platform availability to researchers and customers, including through a Select Release Program unveiled at the AGBT meeting in February 2020. The company has collaborative agreements and research grants with organizations including the Chan Zuckerberg Initiative, the Bill & Melinda Gates Foundation, Oregon Health State University, and Harvard University. ReadCoor, based in Cambridge, MA and led by CEO Shawn Marcell, develops a panomic spatial sequencing platform built around Fluorescent in situ Sequencing (FISSEQ). FISSEQ simultaneously integrates high-throughput sequencing with three-dimensional morphometric analysis to map molecular information in tissue context. The platform is marketed to researchers, clinicians, pharmaceutical and diagnostics companies for spatially resolved omics. ReadCoor highlights FISSEQ’s ability to provide reads without known gene targets, enabling detection of mutated or unexpected sequences. The company intends to use grant funding to spatially map cortical cells for the Human Cell Atlas and to help benchmark in situ technologies. The article notes a grant award but reports the amount as undisclosed. ReadCoor commercializes FISSEQ (fluorescent in situ sequencing), a high‑throughput spatial gene sequencing technology that simultaneously reads thousands of RNAs and visualizes their 3D coordinates in whole cells and tissues. The company completed an oversubscribed $23 million Series A financing round concurrent with its launch from Harvard’s Wyss Institute. ReadCoor holds an exclusive worldwide license to FISSEQ from Harvard’s Office of Technology Development and is positioning the platform as the first true merge of imaging and sequencing to deliver pan‑omic spatial data. The company plans to provide sequencing systems, spatial sequencing services, and diagnostics to researchers, clinicians, pharma and diagnostics companies, and says it will begin offering sequencing services to academia and industry almost immediately while shipping early commercial systems in the near future. FISSEQ has been used in Wyss‑led connectomics work funded by IARPA and has demonstrated utility in oncology, including a breast cancer study slated for publication next year. ReadCoor expects the platform to support drug discovery, pathway analysis and target identification, pathogen identification, regenerative medicine, immuno‑oncology, gene therapy, and neurological disease research.

Total raised

$50M

Funding rounds

3

Latest round

Series B

Latest activity

Jan 2020